• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses. 2015 Jan 4. doi: 10.1111/irv.12301. [Epub ahead of print]
[h=1]Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial.[/h] Coleman BL[SUP]1[/SUP], Fadel SA, Drews SJ, Hatchette TF, McGeer AJ.
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Healthcare workers may be exposed to people with respiratory viral infections more often than other working adults. Understanding the risk and the effectiveness of different preventive measures is of great importance.
[h=4]OBJECTIVES:[/h] To estimate adherence to prophylactic antiviral medication for a full influenza season, to the compare efficacy of antiviral prophylaxis to that of the seasonal influenza vaccine and to identify exposures that increase risk of acute respiratory illnesses (ARI) in healthy adults.
[h=4]METHODS:[/h] Participants were randomized 1:2 to receive the 2008-2009 influenza vaccine or daily prophylaxis with 10 mg of zanamivir during the season. Web-based questionnaires collected information on demographics, symptoms, exposures, medication use and side effects.
[h=4]RESULTS:[/h] Sixty-four healthy adults were recruited in November 2008. Three of 40 active participants discontinued zanamivir due to side effects; the remaining 37 took >85% of scheduled doses for a median of 121 days. Symptomatic, laboratory-confirmed influenza was detected in one person randomized to zanamivir (2?5%) and 2/20 (10%) who received the vaccine (P = 0?25). Forty-seven participants reported 109 episodes of ARI. Factors associated with an ARI were exposure to a spouse (OR 7?2), child (OR 2?4) or patient (OR 2?0) with symptoms of an ARI in the previous 7 days.
[h=4]CONCLUSIONS:[/h] Breakthrough influenza infection occurred in both vaccinated participants and those receiving antiviral prophylaxis. Most adults were willing and able to comply with season-long prophylaxis. Report of recent exposure to family members and patients with an ARI increased the risk of developing an ARI in healthy adults.
? 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.


[h=4]KEYWORDS:[/h] Adult; antiviral; influenza; respiratory tract infections

PMID: 25557838 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25557838
 
Back
Top Bottom